Blood mRNA biomarkers for detection of treatment response in acute pulmonary exacerbations of cystic fibrosis

Thorax

Volumn 68, Issue 10, 2013, Pages 929-937

  Nick, J A ^a,b   Sanders, L A ^a,b   Ickes, B ^a   Briones, N J ^a   Caceres, S M ^a   Malcolm, K C ^a   Brayshaw, S J ^a   Chacon, C S ^a,b   Barboa, C M ^a   Jones, M C ^a   St Clair, C ^a   Taylor Cousar, J L ^a,b   Nichols, D P ^a,b   Sagel, S D ^a,c   Strand, M ^a   Saavedra, M T ^a,b  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBAPENEM; CD163 ANTIGEN; CD36 ANTIGEN; CD64 ANTIGEN; CEFAZOLIN; HEPARANASE; INTERLEUKIN 32; LEVOFLOXACIN; MESSENGER RNA; MONOBACTAM DERIVATIVE; NAFCILLIN; PLEXIN; STEROID; TOLL LIKE RECEPTOR 2; VANCOMYCIN; VERSICAN;

ACUTE DISEASE; ADAM9 GENE; ADULT; ARTICLE; BLOOD SAMPLING; CD163 GENE; CD36 GENE; CD64 GENE; COHORT ANALYSIS; CONTROLLED STUDY; CSPG2 GENE; CYSTIC FIBROSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; GENE; GENE EXPRESSION; HCA112 GENE; HPSE GENE; HUMAN; IL32 GENE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSISTENT INFECTION; PLXND1 GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY TRACT INFECTION; RISK REDUCTION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; TLR2 GENE; TREATMENT RESPONSE; VALIDATION PROCESS;

CYSTIC FIBROSIS; LYMPHOCYTE BIOLOGY; NEUTROPHIL BIOLOGY; RESPIRATORY INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LUNG; MALE; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPUTUM; TREATMENT OUTCOME;

EID: 84884596611     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202278     Document Type: Article

References (35)

1. Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182: 627-32.
2. Sanders DB, Bittner RC, Rosenfeld M, et al. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011; 46: 393-400.
3. Ordonez CL, Henig NR, Mayer-Hamblett N, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 1471-5. (Pubitemid 38037331)
4. Smith AL, Redding G, Doershuk C, et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988; 112: 547-54.
5. Wolter JM, Rodwell RL, Bowler SD, et al. Cytokines and inflammatory mediators do not indicate acute infection in cystic fibrosis. Clin Diagn Lab Immunol 1999; 6: 260-5. (Pubitemid 29124975)
6. Nixon LS, Yung B, Bell SC, et al. Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med 1998; 157: 1764-9.
7. Saavedra MT, Hughes GJ, Sanders LA, et al. Circulating RNA transcripts identify therapeutic response in cystic fibrosis lung disease. Am J Respir Crit Care Med 2008; 178: 929-38.
8. Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125: 1S-39S. (Pubitemid 38096189)
9. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001; 139: 359-65. (Pubitemid 32889511)
10. Regelmann WE, Elliott GR, Warwick WJ, et al. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990; 141: 914-21. (Pubitemid 20157719)
11. Pan W. Akaike's information criterion in generalized estimating equations. Biometrics 2001; 57: 120-5. (Pubitemid 32200145)
12. Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature 2008; 451: 949-52. (Pubitemid 351301751)
13. Pepe MS, Thompson ML. Combining diagnostic test results to increase accuracy. Biostatistics 2000; 1: 123-40. (Pubitemid 33213526)
14. Cystic Fibrosis Foundation. 2009 Patient Registry Center Director Report, 2009.
15. Gibot S, Bene MC, Noel R, et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 2012; 186: 65-71.
16. Nuutila J. The novel applications of the quantitative analysis of neutrophil cell surface FcgammaRI (CD64) to the diagnosis of infectious and inflammatory diseases. Curr Opin Infect Dis 2010; 23: 268-74.
17. Bhandari V, Wang C, Rinder C, et al. Hematologic profile of sepsis in neonates: neutrophil CD64 as a diagnostic marker. Pediatrics 2008; 121: 129-34.
18. Shim J, Karin M. The control of mRNA stability in response to extracellular stimuli. Mol Cells 2002; 14: 323-31. (Pubitemid 41582954)
19. Ovstebo R, Lande K, Kierulf P, et al. Quantification of relative changes in specific mRNAs from frozen whole blood - methodological considerations and clinical implications. Clin Chem Lab Med 2007; 45: 171-6. (Pubitemid 46294686)
20. Carrol ED, Salway F, Pepper SD, et al. Successful downstream application of the Paxgene Blood RNA system from small blood samples in paediatric patients for quantitative PCR analysis. BMC Immunol 2007; 8: 20.
21. Salva PS, Doyle NA, Graham L, et al. TNF-alpha, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients. Pediatr Pulmonol 1996; 21: 11-19.
22. Cunningham S, McColm JR, Mallinson A, et al. Duration of effect of intravenous antibiotics on spirometry and sputum cytokines in children with cystic fibrosis. Pediatr Pulmonol 2003; 36: 43-8. (Pubitemid 36734765)
23. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-56. (Pubitemid 37430625)
24. Stelmach I, Korzeniewska A, Stelmach W, et al. Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis. Ann Allergy Asthma Immunol 2005; 95: 372-80. (Pubitemid 41483732)
25. Tirouvanziam R, Conrad CK, Bottiglieri T, et al. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci 2006; 103: 4628-33.
26. Holl EK, O'Connor BP, Holl TM, et al. Plexin-D1 is a novel regulator of germinal centers and humoral immune responses. J Immunol 2011; 186: 5603-11.
27. Hirose J, Kawashima H, Yoshie O, et al Versican interacts with chemokines and modulates cellular responses. J Biol Chem 2001; 276: 5228-34.
28. Van den Heuvel MM, Tensen CP, van As JH, et al. Regulation of CD 163 on human macrophages: cross-linking of CD163 induces signaling and activation. J Leukoc Biol 1999; 66: 858-66. (Pubitemid 29532050)
29. Kim SH, Han SY, Azam T, et al. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005; 22: 131-42.
30. Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol 2006; 6: 633-43. (Pubitemid 44298213)
31. Namba K, Nishio M, Mori K, et al. Involvement of ADAM9 in multinucleated giant cell formation of blood monocytes. Cell Immunol 2001; 213: 104-13. (Pubitemid 34194831)
32. Jimenez-Dalmaroni MJ, Xiao N, Corper AL, et al. Soluble CD36 ectodomain binds negatively charged diacylglycerol ligands and acts as a co-receptor for TLR2. PLoS One 2009; 4:e7411.
33. Parker W. Distribution and functions of the novel membrane-spanning four-domains subfamily A member HCA112 (Thesis). University of Adelaide 2009: 1-96.
34. Sabroe I, Jones EC, Whyte MK, et al. Regulation of human neutrophil chemokine receptor expression and function by activation of Toll-like receptors 2 and 4. Immunology 2005; 115: 90-8. (Pubitemid 40593295)
35. Ratjen F, Saiman L, Mayer-Hamblett N, et al. Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa. Chest 2012; 142: 1259-66.